‘s stock had its “hold” rating reiterated by Cantor Fitzgerald in a research report issued to clients and investors on Friday. They presently have a $2.00 price target on the biopharmaceutical company’s stock.
‘s stock had its “hold” rating reiterated by Cantor Fitzgerald in a research report issued to clients and investors on Friday. They presently have a $2.00 price target on the biopharmaceutical company’s stock.